Mymd Pharmaceuticals, Inc. (MYMD) SEC Filing 8-K Material Event for the period ending Monday, August 15, 2022

Mymd Pharmaceuticals, Inc.

CIK: 1321834 Ticker: MYMD

View differences made from one to another to evaluate Mymd Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Mymd Pharmaceuticals, Inc..


Assess how Mymd Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Mymd Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Mymd Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: MYMD
CIK: 1321834
Form Type: 8-K Corporate News
Accession Number: 0001493152-22-023354
Submitted to the SEC: Wed Aug 17 2022 5:16:30 PM EST
Accepted by the SEC: Wed Aug 17 2022
Period: Monday, August 15, 2022
Industry: In Vitro And In Vivo Diagnostic Substances
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: